FDA Updates List of Warning Letters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Updates List of Warning Letters


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has updated its website to include the latest Warning Letters issued to pharmaceutical companies by the Office of Prescription Drug Promotion and the Center for Drug Evaluation and Research (CDER).

Improper training and a lack of written procedures were among some of the citation trends. Deviations from cGMP in the manufacture of APIs cited by CDER include:

  • Failure to use dedicated production areas when performing operations with beta-lactam products.
  • Failure to have laboratory records that include complete data derived from all tests conducted to ensure compliance with established specifications and standards.
  • Failure to ensure laboratory instrumentation for assuring the quality of APIs is calibrated according to written procedures and an established schedule.
  • Failure to have a written procedure to investigate out-of-specification results.
  • Failure to ensure proper training.
  • Failure to ensure batch production records are prepared for each API and include complete information relating to the production and control of each batch.
  • Failure of quality unit to review and approve all appropriate quality related documents.
  • Failure of your quality unit to establish written procedures.
  • Failure to validate those operations critical to the quality and purity of the API.

Violations in regulations for finished pharmaceuticals include:

  • Not thoroughly investigating the failure of a batch to meet its specifications whether or not the batch has already been distributed.
  • Not establishing the reliability of the supplier’s analyses through appropriate validation of the supplier’s test results at appropriate intervals.
  • Not establishing scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity.
  • Not establishing or following appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile.

Warning Letters issued by the Office of Prescription Drug Promotion in 2012 cite drug manufacturing companies for overstating efficacy of products, misbranding, presenting misleading information, making unsubstantiated claims, and omitting risk information from advertising materials in a variety of media outlets.

A complete list of FDA-issued Warning Letters can be found at FDA.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here